BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3439884)

  • 1. Kinetics of hydrolysis in vitro of nornitrogen mustard, a metabolite of phosphoramide mustard and cyclophosphamide.
    Hemminki K; Alhonen A; Linkola E; Hesso A
    Arch Toxicol; 1987 Dec; 61(2):126-30. PubMed ID: 3439884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
    Hemminki K
    Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of new metabolites of phosphoramide and nor-nitrogen mustards and cyclophosphamide in rat urine using ion cluster techniques.
    Chan KK; Hong SC; Watson E; Deng SK
    Biomed Environ Mass Spectrom; 1986 Mar; 13(3):145-54. PubMed ID: 2938656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA-binding products of nornitrogen mustard, a metabolite of cyclophosphamide.
    Hemminki K
    Chem Biol Interact; 1987 Jan; 61(1):75-88. PubMed ID: 3815587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of phosphoramide mustard hydrolysis in aqueous solution.
    Watson E; Dea P; Chan KK
    J Pharm Sci; 1985 Dec; 74(12):1283-92. PubMed ID: 4087195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alkylating properties of phosphoramide mustard.
    Colvin M; Brundrett RB; Kan MN; Jardine I; Fenselau C
    Cancer Res; 1976 Mar; 36(3):1121-6. PubMed ID: 1253171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gas chromatographic-mass spectrometric assay for N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in rat plasma.
    Lu H; Chan KK
    J Chromatogr B Biomed Appl; 1996 Apr; 678(2):219-25. PubMed ID: 8738025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
    Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
    Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.
    Struck RF; Kirk MC; Witt MH; Laster WR
    Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-(2-hydroxyethyl)-N-[2-(7-guaninyl)ethyl]amine, the putative major DNA adduct of cyclophosphamide in vitro and in vivo in the rat.
    Benson AJ; Martin CN; Garner RC
    Biochem Pharmacol; 1988 Aug; 37(15):2979-85. PubMed ID: 3395373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent DNA-Protein Cross-Linking by Phosphoramide Mustard and Nornitrogen Mustard in Human Cells.
    Groehler A; Villalta PW; Campbell C; Tretyakova N
    Chem Res Toxicol; 2016 Feb; 29(2):190-202. PubMed ID: 26692166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.
    Juma FD; Rogers HJ; Trounce JR
    Br J Clin Pharmacol; 1980 Oct; 10(4):327-35. PubMed ID: 7448105
    [No Abstract]   [Full Text] [Related]  

  • 13. Protonation of phosphoramide mustard and other phosphoramides.
    Gamcsik MP; Ludeman SM; Shulman-Roskes EM; McLennan IJ; Colvin ME; Colvin OM
    J Med Chem; 1993 Nov; 36(23):3636-45. PubMed ID: 8246232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
    Momerency G; Van Cauwenberghe K; Slee PH; Van Oosterom AT; De Bruijn EA
    Biol Mass Spectrom; 1994 Mar; 23(3):149-58. PubMed ID: 8148406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of cyclophosphamide metabolites by gas chromatography and thermionic specific detection. Interindividual differences in hepatic biotransformation of cyclophosphamide in man in vitro.
    Sessink PJ; Vaes WH; van den Broek PH; Noordhoek J; Bos RP
    J Chromatogr B Biomed Appl; 1995 Nov; 673(2):205-12. PubMed ID: 8611954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
    Hong PS; Srigritsanapol A; Chan KK
    Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Half-life of oxazaphosphorines in biological fluids.
    Sladek NE; Powers JF; Grage GM
    Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites.
    Jardine I; Brundrett R; Colvin M; Fenselau C
    Cancer Treat Rep; 1976 Apr; 60(4):403-8. PubMed ID: 1277214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
    Sladek NE; Doeden D; Powers JF; Krivit W
    Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the metabolism and mode of action of cyclophosphamide.
    Fenselau C
    J Assoc Off Anal Chem; 1976 Sep; 59(5):1028-36. PubMed ID: 965325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.